SUPPRESSION AND REGENERATION PROMOTING EFFECT OF LOW MOLECULAR WEIGHT COMPOUND ON CANCER AND FIBROSIS
申请人:NATIONAL UNIVERSITY CORPORATION TOTTORI UNIVERSITY
公开号:US20190055249A1
公开(公告)日:2019-02-21
To obtain a novel therapeutic drug for a malignant tumor or fibrosis. Used is a compound represented by formula (1), a salt thereof, or a solvate thereof. Also used is a therapeutic drug for a malignant tumor or a therapeutic drug for fibrosis, comprising a compound represented by formula (1), a salt thereof, or a solvate thereof.
Coppens,G., Bulletin des Societes Chimiques Belges, 1960, vol. 69, p. 413 - 421
作者:Coppens,G.
DOI:——
日期:——
Solution-phase synthesis of ICG-001, a β-turn peptidomimetic molecule inhibitor of β-catenin–Tcf-mediated transcription
作者:Alessandro Piergentili、Fabio Del Bello、Francesco Gentili、Mario Giannella、Wilma Quaglia、Cristian Vesprini、Russell J. Thomas、Graeme M. Robertson
DOI:10.1016/j.tet.2007.10.048
日期:2007.12
The solution-phase synthesis of the beta-turn peptidomimetic ICG-001, a selective inhibitor of Wnt/beta-catenin signalling, which has been found to be important for both initiation and progression of cancers of different tissues and has been exploited as an extremely useful chemogenomic tool, was developed. This route is particularly suitable for the multigram scale preparation of ICG-001. (c) 2007 Elsevier Ltd. All rights reserved.